"Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS"
2022-06-29
عنوان الدراسة
"Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS"
داعم الدراسة
Eagle Pharmaceuticals
دواء الدراسة
Dantrolene
رقم بروتوكول الدراسة
EGL-4104-C-1502
حالة الدراسة
Completed
موقع الدراسة
KFMC
مرحلة الدراسة
2
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。